Miniatura

Fitxers

901462.pdf (825.9 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-09-01

Llicència de publicació

cc-by-nc-nd (c) Pascual, Tomás et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/223564

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.esmoop.2025.105572

Resum

Background The SOLTI-1303-PATRICIA trial (NCT02448420) is a phase II study investigating palbociclib and trastuzumab, with or without endocrine therapy, in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This manuscript presents final overall survival (OS) results and biomarker analyses. Patients and methods Patients previously treated with trastuzumab and two to four regimens were eligible. For estrogen receptor (ER)-negative disease (cohort A), patients received palbociclib and trastuzumab. For ER-positive disease, patients were randomized 1 : 1 to cohort B1 (no additional therapy) or B2 (letrozole). OS and long-term progression-free survival (PFS) were pre-defined secondary endpoints. Kaplan–Meier curves and stratified Cox models were used. Results Among 71 patients, median OS was 29.8 months [95% confidence interval (CI) 20.9-38.0 months]; 4-year OS rates were 13.3% (A), 35.7% (B1), and 32.3% (B2). PAM50 luminal subtypes showed better OS than non-luminal subtypes (38.0 versus 26.6 months). Exploratory biomarker analyses found luminal-related genes associated with better long-term survival, while basal and proliferation-related genes were linked to resistance. Higher luminal A, luminal B, and previously reported chemo-endocrine scores correlated with favorable prognoses. Conclusions These findings highlight the relevance of gene expression profiling in HER2-positive breast cancer and support biomarker-driven patient selection. Long-term PATRICIA results validate the potential of non-chemotherapy-based approaches in HR-positive/HER2-positive MBC.

Matèries

Tractament adjuvant del càncer, Medicaments antineoplàstics, Càncer de mama, Metàstasi

Matèries (anglès)

Adjuvant treatment of cancer, Antineoplastic agents, Breast cancer, Metastasis

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

PASCUAL, Tomás, VILLACAMPA, Guillermo, OLIVEIRA, Mafalda, ESCRIVÁ DE ROMANÍ, Santiago, PERNAS, Sònia, PARÉ BRUNET, Laia, ADAMO, Barbara, MARTÍNEZ FRAIZ, Elena, CORTÉS CASTÁN, Javier, PERELLÓ MARTORELL, Antonia, GALÁN, M., MELÉ, M., VILLANUEVA, Lorea, GONZÁLEZ RODRÍGUEZ, Marta, TOLOSA, Pablo, GONZÁLEZ FARRÉ, Blanca, GALVÁN, Patricia, CANES, Jordi, NUCIFORO, Paolo, FERRERO CAFIERO, Juan manuel, GONZÁLEZ FARRÉ, Xavier, VILLAGRASA, Patricia, PRAT APARICIO, Aleix, CIRUELOS, Eva. Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial. _ESMO Open_. 2025. Vol. 10, núm. 9. [consulta: 8 de febrer de 2026]. ISSN: 2059-7029. [Disponible a: https://hdl.handle.net/2445/223564]

Exportar metadades

JSON - METS

Compartir registre